COME TOGETHER, RIGHT NOW—OVERSEAS
It’s a novel idea in drug development: instead of a system built to benefit shareholders, a new “open-source” platform could borrow best practices from software like Linux and Firefox and potentially energize the race to end COVID-19. Merck’s initiative subsidizes access for 105 countries, mostly in Africa and Asia, and of believes his company could market the drug for about $20 per dose—less than 3% of
